Europe Transplant Market Size, Share, COVID-19 Impact, And Trends By Type (Tissue Transplant, Organ Transplant (Living Donors, Deceased Donors)), By Procedure (Autotransplantation, Allotransplantation, Xenotransplantation), By Product (Immunosuppresive Drugs, Preservation Solutions, Organ Transport Systems), And By Country – Forecast From 2023 To 2028

  • Published : May 2023
  • Report Code : KSI061612969
  • Pages : 102
excel pdf power-point

Europe Transplant Market was valued at US$51.947 billion in 2021 and is projected to expand at a CAGR of 5.02% over the forecast period to reach US$73.193 billion by 2028. 

Transplants are also known as grafts or organ transplants where a section of a tissue or a complete organ from its original site is transferred to the area of interest in an individual (same or separate). Thus, the transplanted organ or graft continues to receive nourishment from the new and healthy environment. The prevalence of chronic diseases is one of the major factors driving the growth of the Europe transplant market in the forecast period. Furthermore, growing health awareness along with government initiatives regarding organ donation is driving the market growth. However, the shortage of organ donors and incidences of transplant rejection may impede the growth of the Europe transplant market during the forecast period. Additionally, technological advancements will drive market growth in the forecast period and in the upcoming years.

This research study examines the Europe transplant market based on various segments: type, procedure, product, and countries. First, a brief overview of the market details key driving factors and challenges. Next, Porter's five forces model analyzes the emergency shutdown system industry comprehensively. This is followed by industry value chain analysis which determines the companies which are part of the different processes and contributing to various sectors.

The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the Europe transplant market. Moreover, the research study analyzes the overall regulatory framework of the emergency shutdown system sector, offering stakeholders a better understanding of the key factors influencing the overall market environment.

Europe transplant market – Forecasts from 2023 to 2028 are a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape and details strategies of key market players and also plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.

The scope and coverage of the Europe transplant market report are as below:

  • Europe transplant market data tables and charts
  • Market outlook with sections on drivers, restraints, Porter’s, and industry value chain analysis
  • Market assessment by type into tissue transplant, and organ transplant
  • Detailed market trends, analysis, and graphical representation by procedure into autotransplantation, allotransplantation, and xenotransplantation
  • Market assessment by-product into immunosuppressive drugs, preservation solutions, and organ transport systems
  • A 360o view of the demand for Europe transplant market solutions/services across different geographies (United Kingdom, Germany, France, Spain, and Others).

Europe Transplant Market Scope:

 

Report Metric Details
Market Size Value in 2021 US$51.947 billion
Market Size Value in 2028 US$73.193 billion
Growth Rate CAGR of 5.02% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Billion
Segments Covered Type, Procedure, Product, and Country
Regions Covered United Kingdom, Germany, France, Spain, Others
Companies Covered Veloxis Pharmaceuticals A/S, Bridge to Life Ltd., Paragonix Technologies Inc., Novartis AG, XVIVO Perfusion, F. Hoffmann-La Roche AG
Customization Scope Free report customization with purchase

 

Different segments covered under the Europe transplant market report are as below:

  • By Type
    • Tissue Transplant
    • Organ Transplant
      • Living Donors
      • Deceased Donors
  • By Procedure
    • Autotransplantation
    • Allotransplantation
    • Xenotransplantation
  • By Product
    • Immunosuppresive drugs
    • Preservation Solutions
    • Organ Transport Systems
  • By Country
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. EUROPE TRANSPLANT MARKET, BY TYPE

5.1. Introduction

5.2. Tissue Transplant

5.3. Organ Transplant

5.3.1. Living Donors

5.3.2. Deceased Donors

6. EUROPE TRANSPLANT MARKET, BY PROCEDURE

6.1. Introduction

6.2. Autotransplantation

6.3. Allotransplantation

6.4. Xenotransplantation

7. EUROPE TRANSPLANT MARKET, BY PRODUCT

7.1. Introduction

7.2. Immunosuppresive drugs

7.3. Preservation Solutions

7.4. Organ Transport Systems

8. EUROPE TRANSPLANT MARKET, BY COUNTRY

8.1. Introduction

8.2. United Kingdom

8.3. Germany

8.4. France

8.5. Spain

8.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Veloxis Pharmaceuticals A/S

10.2. Bridge to Life Ltd.

10.3. Paragonix Technologies Inc.

10.4. Novartis AG

10.5. XVIVO Perfusion

10.6. F. Hoffmann-La Roche AG

Veloxis Pharmaceuticals A/S

Bridge to Life Ltd.

Paragonix Technologies Inc.

Novartis AG

XVIVO Perfusion

F. Hoffmann-La Roche AG